IO Biotech announced that the University of California Davis Comprehensive Cancer Center has dosed the first patient in its investigator-initiated trial which aims to evaluate IO102-IO103, the company's investigational immune-modulating cancer vaccine, in combination with pembrolizumab in patients with BCG-unresponsive or intolerant, non-muscle invasive bladder cancer (NMIBC). This is one of five investigator-initiated trials IO Biotech is supporting to evaluate IO102-IO103 in combination with different checkpoint inhibitor-based regimens across a variety of cancer types.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.42 USD | -2.07% | -4.05% | -24.47% |
Apr. 26 | IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors | CI |
Apr. 15 | IO Biotech Announces Marjan Shamsaei as Senior Vice President | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.47% | 93.55M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- IOBT Stock
- News IO Biotech, Inc.
- IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial At University of California Davis Comprehensive Cancer Center